Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma

Tumori

Volumn 89, Issue 3, 2003, Pages 263-268

  Luksch, Roberto ^a   Perotti, Daniela ^a   Cefalo, Graziella ^a   Gambacorti Passerini, Carlo ^a   Massimino, Maura ^a   Spreafico, Filippo ^a   Casanova, Michela ^a   Ferrari, Andrea ^a   Terenziani, Monica ^a   Polastri, Daniela ^a   Gambirasio, Felicita ^a   Podda, Marta ^a   Bozzi, Fabio ^a   Ravagnani, Fabrizio ^a   Parmiani, Giorgio ^a   Bellani, Franca Fossati ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Interleukin 2; NK activity; NK cells; Osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; METHOTREXATE; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL ACTIVITY; CELL SUBPOPULATION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOMODULATION; LYMPHOKINE ACTIVATED KILLER CELL; MALE; NATURAL KILLER CELL; OSTEOSARCOMA; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0041927906     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160308900306     Document Type: Article

References (25)

1. Allavena P, Damia G, Colombo T, D'Incalci M, Mantovani A: Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents. Cell Immunol, 120: 250-258, 1989.
2. Gambacorti-Passerini C, Rivoltini L, Supino R, Rodolfo M, Radrizzani M, Fossati G, Parmiani G: Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes. Cancer Res, 48: 2372-2376, 1988.
3. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP: Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest, 102: 322-328, 1998.
4. Neurath MF, Hildner K, Becker C, Schlaak JF, Barbulescu K, Germann T, Schmitt E, Schirmacher P, Haralambous S, Pasparakis M, Meyer Zum Buschenfelde KH, Kollias G, Marker-Hesmann E: Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol, 115: 42-55, 1999.
5. Mackall CL: T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells, 18: 10-18, 2000.
6. Multhoff G, Botzler C, Allenbacher A, Issels R: Effects of ifosfamide on immunocompetent effector cells. Cancer Immunol Immunother: 42: 251-254, 1996.
7. Allavena P, Pirovano P, Bonazzi C, Colombo N, Mantovani A, D'Incalci M: In vitro and in vivo effects of cisplatin on the generation of lymphokine-activated killer cells. J Natl Cancer Inst, 82: 139-142, 1990.
8. Mizutany Y, Bonavida B, Nio Y, Yoshida O: Enhanced susceptibility of cis-diamminedichloroplatinum(II)-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Cancer 71: 1313-1321, 1993.
9. Formelli F, Rossi C, Sensi ML, Parmiani G: Potentiation of adoptive immunotherapy by cis-diamminedichloroplatinum (II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burden. Int J Cancer, 42: 952-957, 1988.
10. Lichtenstein AK, Pende D: Enhancement of natural killer cytotoxicity by cis-diamminedichloroplatinum (II) in vivo and in vitro. Cancer Res, 46: 639-644, 1986.
11. Le Cesne A, Vassal G, Farace F, Spielemann M, Le Chevalier T, Angerin C, Valteau-Couanet D, Fizaki K, Cojean J, Llombard A, Tursz T, Escudier B: Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma? J Immunother, 22: 268-277, 1999.
12. Horton SA, Oldham RK, Yannelli JR: Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2. Cancer Res, 50: 1686-1692, 1990.
13. Dillman RO, Oldham RK, Barth NM, Birch R, Arnold J, West WH: Recombinant Interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J Natl Cancer Inst, 82: 1345-1349,1990.
14. Elias L, Binder M, Mangalik A, Clark D, Morrison B, Altobelli KK, Smith A: Pilot trial of infusional 5-fluorouracil, interleukin-2 and subcutaneous interpheron-alpha for advanced renal cell carcinoma. Am J Clin Oncol, 22: 156-161, 1999.
15. Gez E, Mekori T, Struminger L, Nativ O, Stein A, Haim N, Kuten A: T-cell subpopulation in patients with metastatic renal cell carcinoma treated by recombinant interleukin-2, recombinant interpheron-alpha, 5-fluorouracil, and vinblastine. Cancer Invest, 17: 259-263, 1999.
16. Eton O, Buzaid AC, Bedikian AY, Smith TM, Papadopoulos NE, Ellerhorst JA, Hibberts JL, Legha SS, Benjamin RS: A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy. Cancer, 88: 1703-1709, 2000.
17. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol, 16: 1752-1759, 1998.
18. Naglieri E, Procacci A, Galetta D, Abbate I, Dell'Erba L, Colucci G: Cisplatin, interleukin-2, interferon-alfa and tamoxifen in metastatic melanoma. A phase II study. J Chemother, 11: 150-155, 1999.
19. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP: Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest, 15: 322-328, 1998.
20. Soiffer RJ, Murray C, Shapiro C, Collins H, Chartier S, Lazo S, Ritz J: Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin-2. Clin Cancer Res, 2: 493-499, 1996.
21. Meropol NJ, Barresi GM, Fehniger TA, Hit J, Franklin M, Caligiuri MA: Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother, 46: 318-326, 1998.
22. Nannmark U, Hokland ME, Agger R, Christiansen M, Kjaergaard J, Goldfarb RH, Bagge U, Unger M, Johansson BR, Albertsson PA, Basse PH: Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells. In Vivo, 14: 651-658, 2000.
23. Jurghens H, Winkler K, Gobel U: Bone tumors. In: Pediatric oncology-clinical practice and controversies. Second edition; Pinkerton CR, Plowman PN (Eds), Chapman & Hall Medical Publishers, London UK; chapter 16, pp 417-442, 1997.
24. Meneghetti A, Mariani E, Santi S, Riccio M, Cattini L, Paoletti S, Facchini A: NK binding capacity and lytic activity depend on the expression of ICAM- I on target bone tumors. Int J Oncol, 15: 909-914, 1999.
25. Mariani E, Meneghetti A, Tarozzi A, Cattini L, Facchini A: Interleukin-12 induces efficient lysis of natural killer-sensitive and natural-killer-resistant human osteosarcoma cells: the synergistic effect of interleukin-2. Scand J Immunol, 51: 618-625, 2000.